Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hayman

Showing results (301-310 of 446) with videos related to

Pageof 45
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|October 2, 2012
Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseasesNelson Leung, Morie Gertz, Robert A Kyle, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 24, 2019
Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosisEli Muchtar, Angela Dispenzieri, Dragan Jevremovic, et al.
Leukemia|October 17, 2018
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapseSurbhi Sidana, Nidhi Tandon, Angela Dispenzieri, et al.
Blood Advances|March 2, 2022
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Utkarsh Goel, Stephen M Broski, et al.
Leukemia|February 24, 2021
Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patientsAlissa Visram, Iuliana Vaxman, Abdullah S Al Saleh, et al.
Blood Cancer Journal|January 11, 2023
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myelomaUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Bone Marrow Transplantation|September 5, 2017
A phase 1 trial of <sup>90</sup>Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myelomaA Dispenzieri, A D'Souza, M A Gertz, et al.
Blood Cancer Journal|March 27, 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myelomaMartha Q Lacy, Suzanne R Hayman, Morie A Gertz, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|July 29, 2008
Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathyMartha Q Lacy, Angela Dispenzieri, Suzanne R Hayman, et al.
Pageof 45

Showing results (301-310 of 446) with videos related to

Sort By:
Pageof 45
Clinical Journal of the American Society of Nephrology : CJASN|October 2, 2012
Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseasesNelson Leung, Morie Gertz, Robert A Kyle, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 24, 2019
Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosisEli Muchtar, Angela Dispenzieri, Dragan Jevremovic, et al.
Leukemia|October 17, 2018
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapseSurbhi Sidana, Nidhi Tandon, Angela Dispenzieri, et al.
Blood Advances|March 2, 2022
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Utkarsh Goel, Stephen M Broski, et al.
Leukemia|February 24, 2021
Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patientsAlissa Visram, Iuliana Vaxman, Abdullah S Al Saleh, et al.
Blood Cancer Journal|January 11, 2023
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myelomaUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Bone Marrow Transplantation|September 5, 2017
A phase 1 trial of <sup>90</sup>Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myelomaA Dispenzieri, A D'Souza, M A Gertz, et al.
Blood Cancer Journal|March 27, 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myelomaMartha Q Lacy, Suzanne R Hayman, Morie A Gertz, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|July 29, 2008
Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathyMartha Q Lacy, Angela Dispenzieri, Suzanne R Hayman, et al.
Pageof 45